Inflammatory Bowel Disease News and Research

RSS

Inflammatory bowel disease (IBD) is an ongoing or chronic health problem that causes inflammation and swelling in the digestive tract. The irritation causes bleeding sores called ulcers to form along the digestive tract. This in turn can cause crampy, abdominal pain and severe bloody diarrhea.

Stem Cells' Ability to Respond to Physical Forces Uncovered

A new study from The Hospital for Sick Children (SickKids) and Institut Curie reveals how stem cells sense and respond to their environment, with implications for inflammatory bowel disease and colorectal cancer.

4 Dec 2024

Understanding Gut Inflammation Through RNA Sequencing

This study creates a comprehensive atlas of gastrointestinal cell types, revealing how stem cell-derived INFLAREs drive inflammation in chronic diseases.

29 Nov 2024

Novel Fungal Commensal Shaping Mouse Immune Responses

Researchers from Weill Cornell Medicine have found a fungus in the stomach of mice that may provide a clue to the evolution of fungi in the gastrointestinal tract.

28 Nov 2024

Mapping of Mouse Intestine Sheds Light on Immune Control and Adaptability

The intestine maintains a delicate balance in the body, absorbing nutrients and water while maintaining a healthy relationship with the gut microbiome, but this equilibrium is disrupted in parts of the intestine in conditions such as celiac disease, ulcerative colitis, and Crohn's disease.

22 Nov 2024

Molecule Found to Aid Intestinal Healing and Prevent Tumor Growth in Colorectal Cancer

Researchers at Karolinska Institutet have found a molecule that can both help the intestines to heal after damage and suppress tumor growth in colorectal cancer.

21 Nov 2024

Novel Cellular Atlas of the Human Gastrointestinal Tract

Spatial and single-cell data from 1.6 million cells have been combined to produce the most complete cell map of the human stomach to date.

21 Nov 2024

New Technology Isolates Key Gut Bacteria Linked to Disease

Researchers at UMC Utrecht have created a novel technique that effectively separates a particular subset of gut bacteria that are identified by IgA antibodies from fecal samples.

15 Nov 2024

Intricate Relationship Between Goblet Cells and the Gut Microbiome

In a new study, scientists from the University of California, San Diego have shed light on the crucial function goblet cells—specialized gut-lining cells—play in preserving a balanced and healthy immune environment in the gastrointestinal (GI) tract. Dr. Fernanda Raya Tonetti led the project, and Dr. Cristina Llorente made important contributions.

13 Nov 2024

New Insights Into the Role of p53 in Intestinal Inflammation

A group of scientists from Charité – Universitätsmedizin and the Berlin Institute for Medical Systems Biology of the Max Delbrück Center have provided fresh insight into the pathophysiology of ulcerative colitis an inflammatory bowel disease that affects an estimated five million people globally and is associated with a higher risk of colon cancer.

28 Oct 2024

A Novel Mechanism for Apoptotic Cell Removal in Epithelial Tissues

In a recent discovery, a study team from Kyushu University in Japan has shed light on how the systems defend against illness and injury by identifying a calcium-based mechanism that is essential to the removal of dead cells.

10 Oct 2024

Harnessing the Power of Beneficial Bacteria to Fight Enterobacteriaceae

Antibiotic-resistant bacterial infections often occur in patients with chronic inflammatory intestinal conditions, such as inflammatory bowel disease, and in patients who have taken antibiotics for a long time. Gram-negative bacteria such as Enterobacteriaceae are a common cause of these infections and have few treatment options. Fecal microbiota transplants have shown promise to curb some of these infections, but their composition varies between batches and they aren't always successful.

23 Sep 2024

Microbiotica Secures Approvals to Begin Clinical Studies in EU and UK for New Microbiome Medicines

Microbiotica, a biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), is pleased to announce that it has received regulatory approvals to initiate clinical studies for its first two programmes in advanced melanoma (MELODY-1) and ulcerative colitis (COMPOSER-1) in selected EU countries and the UK. Both studies are due to start shortly, with initial data readouts expected by the end of 2025.

30 Aug 2024